touchCONGRESS

PARP inhibitors as first-line maintenance therapy in ovarian cancer: Using data from SGO 2022 to inform clinical best practice

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Ovarian Cancer, Gynaecological Cancers Watch Time: 60 mins

touchCONGRESS PARP inhibitors as first-line maintenance therapy in ovarian cancer: Using data from SGO 2022 to inform clinical best practice

Watch this two-part activity exploring recent developments in the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Hybrid Annual Meeting on Women’s Cancer 2022.

Part 1: Watch gynaecological cancer expert Prof. Isabelle Ray-Coquard review key data from the SGO Virtual Annual Meeting 2021 Watch Now

Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

  • Part 1: Data Review
Next Chapter
Introduction
Latest efficacy data on PARP inhibitors in the first-line maintenance setting
Latest safety data on PARP inhibitors in the first-line maintenance setting
How could the latest data impact the use of PARP inhibitors in the first-line maintenance treatment of ovarian cancer in clinical practice?
Video Player Controls:
 
Leave Feedback
  • Part 2: Expert interviews
Leave Feedback
Dr Gonzalez Martin
Dr Antonio González-Martín
Watch Time: 17:35 Clínica Universidad de Navarra, Madrid, Spain

Dr Antonio González-Martín considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO 2022.
 
 
Leave Feedback
Dr Sandro Pignata
Watch Time: 10:35 Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy

Dr Sandro Pignata considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO 2022.
 
 
Leave Feedback
Prof. Isabelle Ray-Coquard
Watch Time: 08:08 Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France

Prof. Isabelle Ray-Coquard considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO 2022.
 
 
Leave Feedback
Please Select A Video:
Dr Gonzalez Martin
Dr Antonio González-Martín
 Clínica Universidad de Navarra, Madrid, Spain Watch Time: 17:35 Translations available:
Watch Video
Dr Sandro Pignata
 Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Naples, Italy Watch Time: 10:35 Translations available:
Watch Video
Prof. Isabelle Ray-Coquard
 Centre Léon Bérard, University Claude Bernard Lyon I, Lyon, France Watch Time: 08:08 Translations available:
Watch Video
Leave Feedback
Overview & Learning Objectives
Overview

Get an update on the use of PARP inhibitors as first-line maintenance treatment for ovarian cancer in this two-part activity. Filmed following the SGO Hybrid Annual Meeting on Women’s Cancer 2022.

Learning Objectives
  • Describe efficacy data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
  • Recall the safety data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
  • Evaluate how the latest data may impact the use of PARP inhibitors as first-line maintenance therapy in clinical practice
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from GlaxoSmithKline.
This activity is provided by touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals.

Launch date: 20 April 2022.

Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Feedback

Thank you for your feedback.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72